Investigating GLP-1 RAs reveals their impact on women's health, addressing metabolic disorders, reproductive health, and ...

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

Emerging evidence shows glucose-lowering medications may have the potential to improve chronic obstructive pulmonary disease ...

The investigators note that, from a biological standpoint, there are several avenues through which GLP-1 RAs could lead to suicidality. Possible mechanisms include “hyperactivity of the ...

HealthDay News — Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment 14 days before total joint arthroplasty can minimize risks for complications, according to a study presented at ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.

GLP-1 RA use is associated with better graft and patient survival among kidney transplant recipients with diabetes.

The use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in patients with metabolic dysfunction–associated steatotic liver disease (MASLD) was associated with a reduced risk for new ...

There have been a slew of studies recently supporting the notion that the same mechanisms that help folks ... The diabetes meds in question are called GLP-1 RAs (sometimes abbreviated as GLP ...

Brito, MD, from the Mayo Clinic in Rochester, Minnesota, and colleagues estimated the risk for incident thyroid cancer among adults with type 2 diabetes being treated with GLP-1 RAs versus other ...

Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment 14 days before total joint arthroplasty can minimize risks for complications, according to a study presented at the annual ...